Could treatment with botulinum toxin protect against subsequent infection with COVID-19?

We report comparative results, over three months, of the impact of SARS-CoV2 in our patients injected with botulinum toxin for functional purposes, compared to the general population. Botulinum neurotoxin type A (BoNT/A) is known to block acetylcholine (ACh) as well as many other neuroreceptors and...

Descripción completa

Detalles Bibliográficos
Autores principales: Batifol, D., Finiels, P.J., Galmiche, S., Jammet, P., de Boutray, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205559/
https://www.ncbi.nlm.nih.gov/pubmed/34144245
http://dx.doi.org/10.1016/j.jormas.2021.06.003
Descripción
Sumario:We report comparative results, over three months, of the impact of SARS-CoV2 in our patients injected with botulinum toxin for functional purposes, compared to the general population. Botulinum neurotoxin type A (BoNT/A) is known to block acetylcholine (ACh) as well as many other neuroreceptors and neuromodulators. The recent mention of a potential protective effect of nicotine in COVID 19, by blocking ACh, attracted our attention and guided the present study. Our results show a significant difference between the number of infected individuals in the general population and the number of patients injected with BoNT/A who showed signs of COVID 19.

Ejemplares similares